These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 16367881

  • 1. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
    Kvapil M, Swatko A, Hilberg C, Shestakova M.
    Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
    [Abstract] [Full Text] [Related]

  • 2. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [Abstract] [Full Text] [Related]

  • 3. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
    Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):527-32. PubMed ID: 17115351
    [Abstract] [Full Text] [Related]

  • 4. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.
    Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
    [Abstract] [Full Text] [Related]

  • 5. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
    Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, Chow CC, Shaban J.
    Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416
    [Abstract] [Full Text] [Related]

  • 7. Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.
    Cucinotta D, Smirnova O, Christiansen JS, Kanc K, le Devehat C, Wojciechowska M, López de la Torre M, Liebl A.
    Diabetes Obes Metab; 2009 Jul; 11(7):700-8. PubMed ID: 19476479
    [Abstract] [Full Text] [Related]

  • 8. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
    Raz I, Mouritzen U, Vaz J, Hershkovitz T, Wainstein J, Harman-Boehm I.
    Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
    [Abstract] [Full Text] [Related]

  • 9. A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.
    Guo L, Chen L, Chang B, Yang L, Liu Y, Feng B.
    Diabetes Obes Metab; 2018 Dec; 20(12):2740-2747. PubMed ID: 29961975
    [Abstract] [Full Text] [Related]

  • 10. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P.
    Endocr Pract; 2011 Dec; 17(1):41-50. PubMed ID: 20713345
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V, NovoLog Mix-vs.-Exenatide Study Group.
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [Abstract] [Full Text] [Related]

  • 12. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
    Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A, INITIATE Study Group.
    Diabetes Care; 2005 Feb; 28(2):260-5. PubMed ID: 15677776
    [Abstract] [Full Text] [Related]

  • 13. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S, Sothiratnam R, Sari R, Andersen H, Hiort LC, Rao P.
    Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
    [Abstract] [Full Text] [Related]

  • 14. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.
    Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, Gylvin T, Kawamori R.
    Clin Ther; 2009 Aug; 31(8):1641-51. PubMed ID: 19808125
    [Abstract] [Full Text] [Related]

  • 15. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, Vaag AA.
    BMJ; 2009 Nov 09; 339():b4324. PubMed ID: 19900993
    [Abstract] [Full Text] [Related]

  • 16. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice.
    Ligthelm RJ.
    Prim Care Diabetes; 2009 May 09; 3(2):97-102. PubMed ID: 19285933
    [Abstract] [Full Text] [Related]

  • 17. Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.
    Morgan CL, Evans M, Toft AD, Jenkins-Jones S, Poole CD, Currie CJ.
    Clin Ther; 2011 Jan 09; 33(1):27-35. PubMed ID: 21397771
    [Abstract] [Full Text] [Related]

  • 18. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y, Andersen TH, Gall MA, Christiansen JS, BOOST: Intensify All Trial Investigators.
    Diabetes Res Clin Pract; 2015 Jan 09; 107(1):139-47. PubMed ID: 25498130
    [Abstract] [Full Text] [Related]

  • 19. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
    Valensi P, Shaban J, Benroubi M, Kawamori R, Borzì V, Shah S, Wenying Y, Prusty V, Hansen JB, Gumprecht J, IMPROVE Study Expert Panel.
    Curr Med Res Opin; 2013 Jun 09; 29(6):601-9. PubMed ID: 23488447
    [Abstract] [Full Text] [Related]

  • 20. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.
    Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelová A, Thomsen HF, Kalra S.
    Curr Med Res Opin; 2009 Dec 09; 25(12):2887-94. PubMed ID: 19821654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.